The company was created as a spin-off from the 3B's Research Group and has since focused on tissue engineering and the development of natural-derived biomaterials. Stemmatters offers contract development and manufacturing services for cell-based advanced therapies, exosomes, blood-derived biologics, tissue products, biomaterials, and combination devices. They are a vertically integrated company that can address all product development stages, from exploratory R&D to cGMP production and clinical batch release. Additionally, Stemmatters has an innovative biomaterial product platform that supports the formulation of advanced therapies for multiple indications.